Comparison of Different Acceleration Modes of Transcranial Magnetic Stimulation

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat people with Treatment Resistant Depression (TRD), which is a form of depression that doesn’t improve with standard treatments. The researchers want to compare the effectiveness and safety of two different stimulation schedules—one where participants receive treatment six times a day and another where they get it ten times a day—against a placebo treatment (which is a fake version of the treatment that doesn’t have any active ingredients). The goal is to find a faster and simpler treatment plan for those who struggle with this tough-to-treat condition.

To participate in this trial, individuals must be between 18 and 45 years old, have been diagnosed with major depression, and have not responded to at least two different antidepressant medications. Participants should also be right-handed and be willing to provide consent to join the study. However, people with other mental health issues, serious physical health problems, or certain conditions that could interfere with the study will not be eligible. If chosen, participants can expect to receive one of the stimulation treatments or the placebo while being closely monitored for safety and effectiveness. It’s an opportunity to contribute to research that could lead to better treatment options for depression.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The current episode met the DSM-5 diagnostic criteria for major depression, without psychotic symptoms of the first or recurrent drug-free depressive subjects
• • 2. After a full course of treatment with two or more antidepressants, the patient had no response, and the level of treatment resistance was moderate to severe as assessed by the Maudsley staging method
• • 3.24-item Hamilton depression Scale score ≥20
• • 4.The age ranged from 18 to 45 years, both sexes
• • 5.Right handed
• • 6.Written informed consent was obtained and patients volunteered to participate in the study and be evaluated.
• Exclusion Criteria:
• • 1. Comorbidity with other mental disorders, including schizophrenia, mental retardation, substance dependence, etc.
• • 2. Suffering from serious or unstable physical diseases
• • 3, pregnant, lactating women, women of childbearing age screening period urine HCG test results are positive
• • 4. Subjects with metal objects in the body or other contraindications to MRI scanning
• • 5. There are other conditions considered by the investigator to be inappropriate for participation in the clinical trial.